|
@
DrAbernethyFDA
Silver Spring, MD
|
|
Principal Deputy Commissioner and Acting CIO at @US_FDA
|
|
|
254
Tweetovi
|
70
Pratim
|
6.805
Osobe koje vas prate
|
| Tweetovi |
| Dr. Amy Abernethy proslijedio/la je tweet | ||
|
Dr. Stephen M. Hahn
@SteveFDA
|
30. sij |
|
I had the incredible privilege of addressing the FDA staff today at my first all-hands. I discussed three areas of priority focus – unleashing the power of data, empowering patients and consumers, as well as supporting innovation and competition. pic.twitter.com/m9pLmMx9DN
|
||
|
|
||
| Dr. Amy Abernethy proslijedio/la je tweet | ||
|
Robert M Califf
@califf001
|
31. sij |
|
We will all learn as we go with this. Hats off to Hahn, Abernethy, Woodcock, Shuren, Marks et al for continuing to work on this. @DrAbernethyFDA @FDACommissioner
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
21. sij |
|
Recognize #RareDiseaseDay 2020 with us & join our public meeting on Feb 24 to discuss opportunities and challenges in product development in the era of individualized therapies. We need your thoughts on how to optimize natural history and registry studies. go.usa.gov/xdxg5
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
21. sij |
|
Addressing rare diseases is a priority. Our @US_FDA Office of Orphan Products Development has an incredible technology modernization effort underway to streamline orphan drug designation requests. #rarediseases go.usa.gov/xdxgP pic.twitter.com/2mxBk9UTiv
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
16. sij |
|
The workshop will discuss evaluation needs, gaps, and approaches for medical XR, with the goal of advancing the evaluation of medical XR devices and applications, accelerating development while ensuring safety and efficacy.
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
16. sij |
|
Medical extended reality is growing and we want to hear from you on best evaluation practices in virtual reality and augmented reality in medicine. Join us at our public workshop on March 5 and share your expertise go.usa.gov/xdx4u pic.twitter.com/mODEJpMZZn
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
11. sij |
|
FDA’s Technology Modernization Action Plan is a critical step to get us there
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
7. sij |
|
As part of the @dhsummit at #CES2020, I had the chance to talk to @DrNic1 about all the great ways we are looking to improve our data strategy at FDA. pic.twitter.com/6YDkmRGg4B
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
7. sij |
|
#ICYMI: We announced a public meeting on Modernizing FDA’s Data Strategy today! pic.twitter.com/g37PAsX3Tk
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
7. sij |
|
Thanks to @meggophone for hosting today’s chat with me at #CES2020. We had a great conversation on how FDA is working to modernize our data strategy. #DigitalHealthCES pic.twitter.com/o4l8yCqrrF
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
7. sij |
|
In just a few minutes, I'll be participating in a Q&A at #CES2020 for the #DigitalHealthSummit. I'm excited to be here, and I hope to see you there! Follow live coverage of the event at @US_FDA. pic.twitter.com/SLvznYWFw3
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
20. pro |
|
The research approach used to study the safety &effectiveness of the vaccine was precedent-setting during a public health emergency & may help create a model for future studies under similar circumstances. go.usa.gov/xp7XB
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
20. pro |
|
Late yesterday, we announced the first FDA-approved vaccine for prevention of Ebola virus - a significant public health achievement, that will help protect against Ebola as well as advance U.S. government preparedness efforts. pic.twitter.com/Tg1mwM8Ncg
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
19. pro |
|
Today, FDA issued a draft guidance to provide some clarity regarding evidence needed to demonstrate effectiveness for drugs and biologics. go.usa.gov/xp7bA pic.twitter.com/bQAJsnvfmh
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
9. pro |
|
Have you seen our new CURE ID app? It’s where health care professionals can report on novel uses of existing medicines for patients with difficult-to-treat infectious diseases, making it easier to spot promising new uses for existing drugs. go.usa.gov/xpm2r pic.twitter.com/VGsxnDnm8Y
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
2. pro |
|
Join the workshop to discuss benefits and risks of using artificial intelligence in radiological imaging, including emerging applications such as AI-guided image acquisition and diagnostic radiology workflow automation.
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
2. pro |
|
We want to hear from you on the use of artificial intelligence (AI) in radiological imaging. Join the FDA at a public workshop on the evolving role of AI in radiological imaging Feb. 25-26, 2020 and comment on the open docket on regulations.gov. go.usa.gov/xpPrj pic.twitter.com/MoTLYjD5Mv
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
26. stu |
|
FDA is concerned that people may mistakenly believe that trying CBD “can’t hurt.” Use of any CBD product should always be discussed with a health care provider. To read more about the potential risks see FDA’s Consumer Update: go.usa.gov/xpRbz
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
26. stu |
|
This week, FDA provided an update for consumers about CBD. Importantly, consumers should know there is limited available information about CBD, including about its effects on the body. go.usa.gov/xpRbz
|
||
|
|
||
|
Dr. Amy Abernethy
@DrAbernethyFDA
|
25. stu |
|
There are number of questions regarding CBD’s safety and there are real risks that need to be considered. There is significant interest in CBD and we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products.
|
||
|
|
||